S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NASDAQ:INVA

Innoviva - INVA Stock Forecast, Price & News

$11.15
0.00 (0.00%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.11
$11.26
50-Day Range
$10.73
$13.02
52-Week Range
$10.64
$20.71
Volume
470,680 shs
Average Volume
986,828 shs
Market Capitalization
$778.05 million
P/E Ratio
5.39
Dividend Yield
N/A
Price Target
$15.17

Innoviva MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
36.0% Upside
$15.17 Price Target
Short Interest
Bearish
13.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
0.84mentions of Innoviva in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$32,610 Bought Last Quarter
Proj. Earnings Growth
-8.76%
From $1.37 to $1.25 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

601st out of 1,009 stocks

Pharmaceutical Preparations Industry

290th out of 494 stocks


INVA stock logo

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Innoviva (INVA) Stock Moves -1.06%: What You Should Know
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Company Calendar

Last Earnings
10/27/2021
Today
3/31/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
5
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$15.17
High Stock Price Forecast
$22.50
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+36.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$213.92 million
Pretax Margin
86.60%

Debt

Sales & Book Value

Annual Sales
$331.34 million
Cash Flow
$2.28 per share
Book Value
$8.11 per share

Miscellaneous

Free Float
69,162,000
Market Cap
$778.05 million
Optionable
Optionable
Beta
0.56

Social Links


Key Executives

  • Pavel Raifeld
    Chief Executive Officer
  • Marianne Zhen
    Secretary & Chief Accounting Officer













INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price forecast for 2023?

3 brokerages have issued 12-month price targets for Innoviva's shares. Their INVA share price forecasts range from $10.00 to $22.50. On average, they anticipate the company's stock price to reach $15.17 in the next twelve months. This suggests a possible upside of 36.0% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2023?

Innoviva's stock was trading at $13.25 at the beginning of the year. Since then, INVA shares have decreased by 15.8% and is now trading at $11.15.
View the best growth stocks for 2023 here
.

Are investors shorting Innoviva?

Innoviva saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,870,000 shares, an increase of 5.8% from the February 28th total of 8,380,000 shares. Based on an average daily trading volume, of 706,600 shares, the short-interest ratio is currently 12.6 days. Currently, 13.2% of the shares of the stock are short sold.
View Innoviva's Short Interest
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.47. The biotechnology company earned $97.86 million during the quarter. Innoviva had a net margin of 64.56% and a trailing twelve-month return on equity of 18.81%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.06%), Dimensional Fund Advisors LP (4.60%), Millennium Management LLC (3.06%), Systematic Financial Management LP (2.80%), Assenagon Asset Management S.A. (2.45%) and LSV Asset Management (2.35%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $11.15.

How much money does Innoviva make?

Innoviva (NASDAQ:INVA) has a market capitalization of $778.05 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.07 on an earnings per share basis.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 3/31/2023 by MarketBeat.com Staff